| Limitation . | Study . | . | . | . | . | . | . | . | . | . |
|---|---|---|---|---|---|---|---|---|---|---|
| . | ALCS1 . | ALCS2 . | BAT . | JTI . | PMI . | RJR . | FDA . | LEVY1 . | LEVY2 . | UM . |
| Deaths not removed during follow-up | ✓ a | ✓ | ✓ | |||||||
| Current smokers not subdivided by amount smoked | ✓ | ✓ | ✓ | ✓ | ✓ | ✓ | ✓ | ✓ | ✓ | |
| Former smokers not subdivided by time quit | ✓ | |||||||||
| Re-initiation not allowed for in null scenario | ✓ | ✓ | ✓ | ✓ | ||||||
| Re-initiation not allowed for in alternative scenario | (✓)b | ✓ | ✓ | |||||||
| Do not fully allow for initiation of both products | ✓ | ✓ | ✓ | ✓ | ||||||
| Former smoker TTPs independent of previous product used | ✓ | ✓ | ✓ | ✓ | ||||||
| TTPs not age-dependent | ✓ | N/A | ||||||||
| Decreased cigarette consumption or risk in dual users is not accounted for | ✓ | ✓ | ✓ | ✓ | ✓ | N/A | ||||
| Disease risks do not depend on the full tobacco history | ✓ | ✓ | ✓ | ✓ | ||||||
| Age-specific risk in never tobacco users is assumed invariant over the follow-up period | ✓ | ✓ | ✓ | ✓ | ✓ | ✓ | ✓ | ✓ | ✓ | |
| Results are not presented by age | ✓ | ✓ | ✓ | |||||||
| Results are not presented by gender | ✓ | ✓ | ✓ | ✓ |
| Limitation . | Study . | . | . | . | . | . | . | . | . | . |
|---|---|---|---|---|---|---|---|---|---|---|
| . | ALCS1 . | ALCS2 . | BAT . | JTI . | PMI . | RJR . | FDA . | LEVY1 . | LEVY2 . | UM . |
| Deaths not removed during follow-up | ✓ a | ✓ | ✓ | |||||||
| Current smokers not subdivided by amount smoked | ✓ | ✓ | ✓ | ✓ | ✓ | ✓ | ✓ | ✓ | ✓ | |
| Former smokers not subdivided by time quit | ✓ | |||||||||
| Re-initiation not allowed for in null scenario | ✓ | ✓ | ✓ | ✓ | ||||||
| Re-initiation not allowed for in alternative scenario | (✓)b | ✓ | ✓ | |||||||
| Do not fully allow for initiation of both products | ✓ | ✓ | ✓ | ✓ | ||||||
| Former smoker TTPs independent of previous product used | ✓ | ✓ | ✓ | ✓ | ||||||
| TTPs not age-dependent | ✓ | N/A | ||||||||
| Decreased cigarette consumption or risk in dual users is not accounted for | ✓ | ✓ | ✓ | ✓ | ✓ | N/A | ||||
| Disease risks do not depend on the full tobacco history | ✓ | ✓ | ✓ | ✓ | ||||||
| Age-specific risk in never tobacco users is assumed invariant over the follow-up period | ✓ | ✓ | ✓ | ✓ | ✓ | ✓ | ✓ | ✓ | ✓ | |
| Results are not presented by age | ✓ | ✓ | ✓ | |||||||
| Results are not presented by gender | ✓ | ✓ | ✓ | ✓ |
N/A = not applicable; TTP = tobacco transition probability.
aBut a correction for differential survival is described.
bAllows only for re-initiation as MRTP.
| Limitation . | Study . | . | . | . | . | . | . | . | . | . |
|---|---|---|---|---|---|---|---|---|---|---|
| . | ALCS1 . | ALCS2 . | BAT . | JTI . | PMI . | RJR . | FDA . | LEVY1 . | LEVY2 . | UM . |
| Deaths not removed during follow-up | ✓ a | ✓ | ✓ | |||||||
| Current smokers not subdivided by amount smoked | ✓ | ✓ | ✓ | ✓ | ✓ | ✓ | ✓ | ✓ | ✓ | |
| Former smokers not subdivided by time quit | ✓ | |||||||||
| Re-initiation not allowed for in null scenario | ✓ | ✓ | ✓ | ✓ | ||||||
| Re-initiation not allowed for in alternative scenario | (✓)b | ✓ | ✓ | |||||||
| Do not fully allow for initiation of both products | ✓ | ✓ | ✓ | ✓ | ||||||
| Former smoker TTPs independent of previous product used | ✓ | ✓ | ✓ | ✓ | ||||||
| TTPs not age-dependent | ✓ | N/A | ||||||||
| Decreased cigarette consumption or risk in dual users is not accounted for | ✓ | ✓ | ✓ | ✓ | ✓ | N/A | ||||
| Disease risks do not depend on the full tobacco history | ✓ | ✓ | ✓ | ✓ | ||||||
| Age-specific risk in never tobacco users is assumed invariant over the follow-up period | ✓ | ✓ | ✓ | ✓ | ✓ | ✓ | ✓ | ✓ | ✓ | |
| Results are not presented by age | ✓ | ✓ | ✓ | |||||||
| Results are not presented by gender | ✓ | ✓ | ✓ | ✓ |
| Limitation . | Study . | . | . | . | . | . | . | . | . | . |
|---|---|---|---|---|---|---|---|---|---|---|
| . | ALCS1 . | ALCS2 . | BAT . | JTI . | PMI . | RJR . | FDA . | LEVY1 . | LEVY2 . | UM . |
| Deaths not removed during follow-up | ✓ a | ✓ | ✓ | |||||||
| Current smokers not subdivided by amount smoked | ✓ | ✓ | ✓ | ✓ | ✓ | ✓ | ✓ | ✓ | ✓ | |
| Former smokers not subdivided by time quit | ✓ | |||||||||
| Re-initiation not allowed for in null scenario | ✓ | ✓ | ✓ | ✓ | ||||||
| Re-initiation not allowed for in alternative scenario | (✓)b | ✓ | ✓ | |||||||
| Do not fully allow for initiation of both products | ✓ | ✓ | ✓ | ✓ | ||||||
| Former smoker TTPs independent of previous product used | ✓ | ✓ | ✓ | ✓ | ||||||
| TTPs not age-dependent | ✓ | N/A | ||||||||
| Decreased cigarette consumption or risk in dual users is not accounted for | ✓ | ✓ | ✓ | ✓ | ✓ | N/A | ||||
| Disease risks do not depend on the full tobacco history | ✓ | ✓ | ✓ | ✓ | ||||||
| Age-specific risk in never tobacco users is assumed invariant over the follow-up period | ✓ | ✓ | ✓ | ✓ | ✓ | ✓ | ✓ | ✓ | ✓ | |
| Results are not presented by age | ✓ | ✓ | ✓ | |||||||
| Results are not presented by gender | ✓ | ✓ | ✓ | ✓ |
N/A = not applicable; TTP = tobacco transition probability.
aBut a correction for differential survival is described.
bAllows only for re-initiation as MRTP.
This PDF is available to Subscribers Only
View Article Abstract & Purchase OptionsFor full access to this pdf, sign in to an existing account, or purchase an annual subscription.
